Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RHOA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RHOA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RHOA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RHOA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RHOA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RHOA_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RHOA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RHOA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RHOA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RHOA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RHOA_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RHOA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003629332 | Oral cavity | NEOLP | response to decreased oxygen levels | 65/2005 | 322/18723 | 3.34e-07 | 1.04e-05 | 65 |
GO:005149532 | Oral cavity | NEOLP | positive regulation of cytoskeleton organization | 50/2005 | 226/18723 | 4.47e-07 | 1.35e-05 | 50 |
GO:004572732 | Oral cavity | NEOLP | positive regulation of translation | 35/2005 | 136/18723 | 5.91e-07 | 1.74e-05 | 35 |
GO:003253532 | Oral cavity | NEOLP | regulation of cellular component size | 73/2005 | 383/18723 | 6.70e-07 | 1.93e-05 | 73 |
GO:004312331 | Oral cavity | NEOLP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 43/2005 | 186/18723 | 8.08e-07 | 2.21e-05 | 43 |
GO:003425033 | Oral cavity | NEOLP | positive regulation of cellular amide metabolic process | 39/2005 | 162/18723 | 8.79e-07 | 2.37e-05 | 39 |
GO:005127115 | Oral cavity | NEOLP | negative regulation of cellular component movement | 70/2005 | 367/18723 | 1.10e-06 | 2.90e-05 | 70 |
GO:006053723 | Oral cavity | NEOLP | muscle tissue development | 75/2005 | 403/18723 | 1.22e-06 | 3.15e-05 | 75 |
GO:003103224 | Oral cavity | NEOLP | actomyosin structure organization | 44/2005 | 196/18723 | 1.42e-06 | 3.58e-05 | 44 |
GO:002240724 | Oral cavity | NEOLP | regulation of cell-cell adhesion | 81/2005 | 448/18723 | 1.54e-06 | 3.83e-05 | 81 |
GO:000715923 | Oral cavity | NEOLP | leukocyte cell-cell adhesion | 70/2005 | 371/18723 | 1.65e-06 | 4.05e-05 | 70 |
GO:004533332 | Oral cavity | NEOLP | cellular respiration | 49/2005 | 230/18723 | 1.85e-06 | 4.45e-05 | 49 |
GO:200014615 | Oral cavity | NEOLP | negative regulation of cell motility | 68/2005 | 359/18723 | 2.01e-06 | 4.77e-05 | 68 |
GO:004211031 | Oral cavity | NEOLP | T cell activation | 86/2005 | 487/18723 | 2.01e-06 | 4.77e-05 | 86 |
GO:000726622 | Oral cavity | NEOLP | Rho protein signal transduction | 34/2005 | 137/18723 | 2.08e-06 | 4.87e-05 | 34 |
GO:000815431 | Oral cavity | NEOLP | actin polymerization or depolymerization | 47/2005 | 218/18723 | 2.11e-06 | 4.91e-05 | 47 |
GO:190313122 | Oral cavity | NEOLP | mononuclear cell differentiation | 77/2005 | 426/18723 | 2.80e-06 | 6.41e-05 | 77 |
GO:003249631 | Oral cavity | NEOLP | response to lipopolysaccharide | 65/2005 | 343/18723 | 3.30e-06 | 7.40e-05 | 65 |
GO:003033614 | Oral cavity | NEOLP | negative regulation of cell migration | 65/2005 | 344/18723 | 3.65e-06 | 7.97e-05 | 65 |
GO:004854532 | Oral cavity | NEOLP | response to steroid hormone | 64/2005 | 339/18723 | 4.45e-06 | 9.55e-05 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RHOA | SNV | Missense_Mutation | | c.118G>C | p.Glu40Gln | p.E40Q | P61586 | protein_coding | deleterious(0.04) | benign(0.41) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RHOA | SNV | Missense_Mutation | | c.13N>T | p.Arg5Trp | p.R5W | P61586 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-AC-A3TM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
RHOA | SNV | Missense_Mutation | | c.13N>T | p.Arg5Trp | p.R5W | P61586 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
RHOA | SNV | Missense_Mutation | | c.373N>C | p.Glu125Gln | p.E125Q | P61586 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RHOA | SNV | Missense_Mutation | rs11552761 | c.50N>C | p.Gly17Ala | p.G17A | P61586 | protein_coding | deleterious(0) | benign(0.422) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RHOA | SNV | Missense_Mutation | | c.118N>C | p.Glu40Gln | p.E40Q | P61586 | protein_coding | deleterious(0.04) | benign(0.41) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
RHOA | SNV | Missense_Mutation | rs11552761 | c.50N>A | p.Gly17Glu | p.G17E | P61586 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-GM-A3XG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
RHOA | insertion | Frame_Shift_Ins | novel | c.561dupA | p.Ser188IlefsTer30 | p.S188Ifs*30 | P61586 | protein_coding | | | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RHOA | insertion | Nonsense_Mutation | novel | c.165_166insAGCAAACTAGATGAGTTCCAAATGTAA | p.Leu55_Ala56insSerLysLeuAspGluPheGlnMetTer | p.L55_A56insSKLDEFQM* | P61586 | protein_coding | | | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
RHOA | SNV | Missense_Mutation | | c.318N>G | p.Phe106Leu | p.F106L | P61586 | protein_coding | deleterious(0.03) | benign(0.324) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |